Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340156 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
A Phase 2 study, sponsored by SynerGene Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02340156 is a Phase 2 study that was terminated before completion, run by SynerGene Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT02340156, a Phase 2 study, was terminated before completion, sponsored by SynerGene Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progression free survival (PFS), overall survival (OS), anti-tumor activity, safety and possibly to evaluate, nanoparticle delivery to tumor site, and the induction of apoptosis in the tumor..
Interventions
- DRUG Temozolomide
- GENETIC SGT-53
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340156
The ClinicalTrials.gov registry entry for NCT02340156 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SynerGene Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT02340156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340156 about?
NCT02340156 is a clinical study titled "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma". This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progres...
What is the current status of trial NCT02340156?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2014-12. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02340156?
The interventions under investigation include: Temozolomide (DRUG), SGT-53 (GENETIC).
Who is sponsoring clinical trial NCT02340156?
This trial is sponsored by SynerGene Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.